logo
Looking for a beautiful, low-maintenance, quiet and long-living cat? This is the breed for you –and everything you need to know

Looking for a beautiful, low-maintenance, quiet and long-living cat? This is the breed for you –and everything you need to know

Yahoo4 days ago
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Russian Blue cat overview
Other names: Archangel Blues
Life expectancy: 15–20 years
Size: 8-10 inches (height), 15–18 inches (length) and 8–15 lb (weight)
Coat: solid steel blue
Eye colour: green eyes
Temperament: devoted, intelligent, sensitive and intuitive
Origin/native country: Russia
Celebrated for their blue-silver coats, elegant build and low-key energy, the Russian Blue is the perfect mix of beauty and grace. As their name suggests, these feline companions hail from Russia – in the bustling port city of Arkhangelsk, to be exact – and they are a naturally occurring breed.
They get their name because of their illustrious blue coat that has a silvery sheen throughout. You might think all this fur requires hours worth of upkeep, but the truth is, Russian Blues are pretty low maintenance on all fronts. This breed can also be a godsend for allergy-prone households because Russian Blues produce less of the allergy-triggering protein found in cats when compared to other breeds.
Another fun fact about this beautiful, long-living breed? They are an intelligent, relatively independent and quiet breed, so are best suited for homes that can match this understated energy. If you're considering bringing a Russian Blue home, you'll find everything you need to know in this guide, including their health conditions, enrichment needs, and more.
Are Russian Blue cats hypoallergenic?
'Russian Blue cats are not truly hypoallergenic, but may suit some owners with mild allergies,' explains vet Dr Rebecca MacMillan. 'This is because Russian Blues produce less Fel d1 protein in their saliva and urine than many other breeds,'.
In the cat realm, Fel d1 is the protein that triggers reactions in those allergic to cats. Therefore, if you are in an allergy-prone household, it's worth reading up on the hypoallergenic cat breeds, like the Siamese, Burmese and the LaPerm, as these pets either produce less of the allergy-triggering protein and/or don't shed too much, which can make them an ideal proposition for allergy sufferers.
Do Russian Blue cats shed?
Russian Blues do shed some of their shimmering coat, but only minimally so this means you won't find too many loose hairs around your home!
'This can also help allergy sufferers as there will be less saliva-coated hair and dander in the environment,' Dr MacMillan says. 'Just remember that very sensitive people may still react.'
For those who would prefer not to have tons of fur all over their clothing, floors and furniture, the non-shedding cat breeds are well worth considering.
How long do Russian Blue cats live?
Russian Blue cats are pretty long-living cats. So much so, many Russian Blues live until they are between 15–20 years of age with the right care.
According to Dr MacMillan, if you want to increase the chances of your cat having a long and healthy life, then there are several things you can do.
'Make sure they are receiving the correct amount of a good quality diet, appropriate for their age and lifestyle,' the vet notes. 'Also monitor their weight closely, as cats that are overweight or obese can have significantly shorter life spans."
Thirdly, Dr MacMillan suggests taking your cat to the vets for routine check-ups and ensuring they have all the recommended vaccinations.
'This will keep them safe from potentially fatal diseases,' she says.
While regular anti-parasite treatment, like the best flea treatments for cats, will also help to keep them healthy, as will regular preventative oral care.
How much grooming does a Russian Blue cat need?
If you're considering adopting a Russian Blue, you'll be pleased to know that these cuties have easy grooming requirements.
'Their short coat only needs brushing once a week to remove any loose hairs,' Dr MacMillan says. 'I also recommend introducing regular oral care from an early age. Many cats will tolerate gentle toothbrushing with cat-safe toothpaste, if you encourage this with positive reinforcement training.'
As Dr MacMillan says, to help keep cat teeth clean, it's important to get into a good teethbrushing routine. It's also well worth learning how to brush your cat's teeth, so that you can avoid dental disease, like stomatitis and gingivitis, and boost your cat's longevity and quality of life.
How much exercise does a Russian Blue cat need?
Russian Blues have moderate exercise needs and are not as demanding as some other cat breeds, like an Abyssinian, Bengal or Siamese, which are all high-energy cat breeds that will want to play with you all the time.
'Around 30 minutes of activity a day should be enough to keep them happy,' Dr MacMillan says.
So, if you plan on bringing a Russian Blue home, the best cat toys and the best automated cat toys will help keep your kitty entertained.
Wisdom Panel Cat DNA Test | Amazon
Not sure exactly what breed your cat is? This kit screens for 70+ breeds, 45 genetic health insights and 25+ physical traits – because knowing every detail about your cat helps you understand how best to care for them. View Deal
Russian Blue health problems
Dental disease is common in many cats and Russian Blues are no different because dental issues in cats often go unnoticed.
'Excessive tartar buildup and gum inflammation can lead to tooth loss,' explains Dr MacMillan. 'That is why preventative oral care is so important.'
Obesity is another health condition common in Russian Blues, as it can be hard to say no to those cute little faces!
'However, obesity is linked to an increased risk of other ailments like diabetes, joint disease, and cancer,' Dr MacMillan highlights. 'Owners must weigh their pet's food out carefully and keep an eye on their cat's body condition, to ensure they don't put on any extra pounds.'
As with many pedigree breeds, hypertrophic cardiomyopathy can be a problem for Russian Blues.
'This condition causes thickening of the muscular heart walls,' the vet explains. 'This affects the heart's ability to effectively pump blood around the body. Heart failure can occur, as well as blood clots and sudden death.'
Hypertrophic cardiomyopathy is an inherited condition so purchasing your kitten from a reputable breeder who has screened their cats will reduce the risk.
Asthma in cats isn't uncommon and it's a respiratory condition that can affect this breed.
'In affected cats, the body overreacts to inhaled allergens leading to inflammation and constriction of the airways,' Dr MacMillan says. 'Asthmatic cats can have breathing difficulties, wheezing, and start open-mouth breathing.'
If any of these symptoms occur, owners must seek urgent help from a vet if their cat is showing any signs of asthma.
'Reducing things like cigarette smoke, air fresheners and scented candles in the environment can help ease symptoms, but many cats will require long-term medication too,' Dr MacMillan adds.
How much does a Russian Blue cost?
Russian Blues are pretty expensive cats. Costing anywhere between $1,400–3,800, their distinct appearance and pleasing personality traits make them particularly desirable – and therefore on the pricier side. This is around the same price tag as a Bengal or Savannah cat.
Though Russian Blues aren't considered to be one of the rarest cat breeds in the US, they aren't your everyday cat you might come across.
Should I get a Russian Blue?
That depends. The long-living Russian Blues are sweet-natured kitties who thrive in human company.
These cats are a relatively quiet breed and can get a bit scared by noisy children, bouncy dogs, or strangers. This is why Dr MacMillan suggests they would be best suited to a peaceful household, perhaps an elderly owner or a family with calmer, older children.
Due to the fact Russian Blues produce less Fel d1 protein in their saliva and urine than many other breed and shed minimally, this breed might also suit allergy sufferers or those who don't want to spend all day picking up after their kitty.
Although they enjoy playing, they also like a bit of alone time and will often take themselves off for a nap.
'They are usually content being left for short periods too, if you need to head out for a bit,' Dr MacMillan adds.
Russian Blue Cats As Pets | Amazon
This book covers the ideal habitat, food, shedding, feeding, diet and diseases – all specific to Russian Blues – and is written to help to those who desire advice and a better understanding for their new or existing companion.View Deal
Read next: Facts about Russian blue cats
Edited by Georgia Guerin.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wes Streeting warned alcohol measures ‘are not sufficient' to stop harm
Wes Streeting warned alcohol measures ‘are not sufficient' to stop harm

Yahoo

time37 minutes ago

  • Yahoo

Wes Streeting warned alcohol measures ‘are not sufficient' to stop harm

Government plans to tackle problem drinking 'are not sufficient to address the scale and complexity of harm', leading health experts have warned. Academics, medics and charities from around the country have urged ministers to take 'ambitious' action to tackle the 'scale of the current crisis'. The Government recently set out plans to improve the health of people in England over the next decade. But in a letter to Health Secretary Wes Streeting, shared with the PA news agency, experts said that the public 'want and deserve' more action to tackle the harms. 'As experts from across alcohol policy, health and treatment, we urge you to revisit the current approach to tackling alcohol harm and commit to an ambitious, evidence-based strategy that reflects the scale of the current crisis,' the letter states. 'The 10-Year health plan for England offered a once-in-a-generation opportunity to shift gear and deliver genuine preventative action that would reverse the rising rates of alcohol-related hospitalisations and deaths we have seen in recent years. 'While the introduction of mandatory alcohol labelling and increased support for community-led schemes is welcome, these measures alone are not sufficient to address the scale and complexity of harm.' The letter has been signed by 34 health leaders from leading health organisations including the Alcohol Health Alliance; the Royal College of Physicians; the Royal College of General Practitioners and the Royal College of Emergency Medicine. The 10 Year Health Plan for England, which was published last month, sets out plans to tackle harmful drinking through alcohol labelling, which will include health warning messages. The document also sets out proposed changes to no and low (NoLo) alcohol products and pledged support for community-led schemes to reduce alcohol harm. Before the 10 Year Plan was released there was speculation over whether the plan would include a ban on alcohol advertising. It was also reported that ministers were exploring the possibility of minimum unit pricing (MUP), a policy which sets the lowest price an alcoholic drink can be sold for. In the new letter, experts have called for a series of measures to tackle alcohol harms, including: – A call for the introduction of MUP in England, as seen in Scotland and Wales. – Giving local authorities the power to regulate hours of sale and online deliveries of alcohol. – For advertising regulations for alcohol to be 'aligned' with those for foods high in fat, salt and sugar. – A change to alcohol tax, linking duties to inflation and ending 'cider exceptionalism'. – More funding and support for local alcohol care teams. The group stresses that 'alcohol is not just the problem of a few'. It points out that every year alcohol contributes to more than a million hospital admissions. And the experts said that across the UK, 30% of the adult population engage in 'risky drinking', and almost one in 25 of all new cancers are estimated to be linked to alcohol. The 10 Year Plan states: 'While many people enjoy a drink in moderation, 4% of people drink as much as 30% of alcohol consumed each year.' But it adds that the estimated total 'societal cost' of alcohol harm in England was £27.4 billion per year in 2021/22. The authors conclude: 'The public want and deserve action, and we stand ready to work with Government to deliver real progress. 'By taking meaningful and co-ordinated action now, the burden of alcohol harm can fall significantly within the term of this Government, with visible results for families, the NHS, crime, and the economy.' The Department of Health and Social Care said it will continue to consider the most effective interventions to reduce alcohol harms. A spokesperson said: 'As we shift from sickness to prevention through our 10-Year Health Plan, we will make it mandatory for alcoholic drinks to display health warnings and nutritional information. 'To improve drug and alcohol treatment services and recovery support in England, the Government has also provided an additional £310 million in 2025/26, on top of the public health grant.' A spokesperson for the Portman Group said: 'Whilst overall alcohol consumption and harms such as binge drinking, underage drinking and anti-social behaviour continue to fall, and the vast majority of people drink within the chief medical officer's low-risk guidance or not at all, we share concerns around rising deaths and those who continue to drink to harmful levels. 'We support further targeted and tailored measures aimed at this group to manage the complex, often interrelated issues underlying harmful consumption and back calls for the further rollout of alcohol care teams and greater integration of care pathways. 'As the alcohol industry regulatory body for marketing, we welcome the chance to work constructively with the Government on the proposals within its 10 year plan to help more consumers make an informed choice and drink moderately.' – Other signatories on the letter include representatives from: the Institute of Alcohol Studies; Alcohol Change UK; the Royal College of Surgeons of England; the Royal Society for Public Health; the British Society of Gastroenterology; World Cancer Research Fund; the Association of Anaesthetists; the Association of Directors of Public Health; the British Association for the Study of the Liver; the Medical Council on Alcohol and the British Medical Association.

Medtronic to announce financial results for its first quarter of fiscal year 2026
Medtronic to announce financial results for its first quarter of fiscal year 2026

Yahoo

time2 hours ago

  • Yahoo

Medtronic to announce financial results for its first quarter of fiscal year 2026

GALWAY, Ireland, Aug. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, August 19, 2025, for its first quarter of fiscal year 2026, which ended on Friday, July 25, 2025, A news release containing summary financial information will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at A video webcast to discuss results will begin at 7:00 a.m. CDT and can be accessed at Within 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at Looking ahead, Medtronic plans to report its fiscal year 2026 second, third, and fourth quarter results on Tuesday, November 18, 2025, February 17, 2026, and Wednesday, May 20, 2026, respectively. Confirmation and additional details will be provided closer to the specific event. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit and follow Medtronic on LinkedIn. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. Contacts:Erika WinkelsPublic Relations+1-763-526-8478 Ryan WeispfenningInvestor Relations+1-763-505-4626 View original content to download multimedia: SOURCE Medtronic plc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Yahoo

time4 hours ago

  • Yahoo

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store